■治疗复发性和/或晚期子宫内膜癌的最佳策略仍未定义。最近,尽管缺乏任何预测生物标志物,pembrolizumab联合乐伐替尼改善了生存结局.我们在这里报告子宫内膜癌患者的肺毒性的长期管理,我们批判性地回顾了目前这种疾病的治疗选择。
■一名严重预处理的子宫内膜癌患者服用pembrolizumab联合lenvatinib治疗1年,达到持续的部分反应,治疗失败时间为18个月,尽管相关的肺毒性并不影响显著的总体临床获益。对这种组合的系统评价强调了尽管有毒性但疗效结果。有趣的是,关于肺毒性的文献综述表明抗血管生成药物在肺空洞的发病机理中的作用,可能与直接治疗活动有关,并公开了预测抗血管生成剂活性的潜在放射学标志。
■我们强调了pembrolizumab联合lenvatinib在当前子宫内膜癌治疗中的疗效,强调正确处理毒性的相关性。
UNASSIGNED: The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of lung toxicity in a patient with endometrial cancer, and we critically review the current therapeutic options for this disease.
UNASSIGNED: A patient with heavily pretreated endometrial cancer took pembrolizumab plus lenvatinib for 1 year, achieving a persistent partial response with a time to treatment failure of 18 months, despite relevant lung toxicity that did not affect the remarkable overall clinical benefit. A systematic review of this combination underlines the efficacy outcome despite toxicity. Interestingly, the literature review on lung toxicity suggested the role of anti-angiogenetic agents in the pathogenesis of lung cavitation, probably related to direct treatment activity, and disclosed a potential radiological sign predictive of the activity of anti-angiogenetic agents.
UNASSIGNED: We underline the efficacy of pembrolizumab plus lenvatinib in the current treatment landscape of endometrial cancer, underscoring the relevance of a correct management of toxicity.